The DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
5-HT Modulation of Dopamine Release in Basal Ganglia in Psilocybin-Induced Psychosis in Man—A PET Study with [11C]raclopride
Abstract
The modulating effects of serotonin on dopamine neurotransmission are not well understood, particularly in acute psychotic states. Positron emission tomography was used to examine the effect of psilocybin on the in vivo binding of [11C]raclopride to D2-dopamine receptors in the striatum in healthy volunteers after placebo and a psychotomimetic dose of psilocybin (n = 7). Psilocybin is a potent indoleamine hallucinogen and a mixed 5-HT2A and 5-HT1A receptor agonist. Psilocybin administration (0.25 mg/kg p.o.) produced changes in mood, disturbances in thinking, illusions, elementary and complex visual hallucinations and impaired ego-functioning. Psilocybin significantly decreased [11C]raclopride receptor binding potential (BP) bilaterally in the caudate nucleus (19%) and putamen (20%) consistent with an increase in endogenous dopamine. Changes in [11C]raclopride BP in the ventral striatum correlated with depersonalization associated with euphoria. Together with previous reports of 5-HT receptor involvement in striatal dopamine release, it is concluded that stimulation of both 5-HT2A and 5-HT1A receptors may be important for the modulation of striatal dopamine release in acute psychoses. The present results indirectly support the hypothesis of a serotonin-dopamine dysbalance in schizophrenia and suggest that psilocybin is a valuable tool in the analysis of serotonin-dopamine interactions in acute psychotic states.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Comparison of the two scans revealed a global 20% decline in [11C]-raclopride (41) binding in the striatum, which is similar to the displacements evoked by amphetamine or other strong releasers of dopamine.”
From Molecular and Functional Imaging Studies of Psychedelic Drug Action in Animals and Humans. (2021) · cites this paper as [96]
In the citing paper
“Furthermore, the decline in the ventral striatum correlated with individual ratings for euphoria and depersonalization.”
From Molecular and Functional Imaging Studies of Psychedelic Drug Action in Animals and Humans. (2021) · cites this paper as [96]
In the citing paper
“The other explanation of psychedelics' ability to facilitate altered states of consciousness characterized by heightened introspection and diminished ego boundaries is their influence on 5-HT1A [64] and 5-HT2B [65], and interacting with the dopaminergic [66] and glutamatergic systems [67].”
From Mindfulness meditation and psychedelics: potential synergies and commonalities (2023) · cites this paper as [66]
Citations
Cites
Simplified Reference Tissue Model for PET Receptor Studies
Lammertsma, A. A., & Hume, S. P. (1996) · NeuroImage · doi:10.1006/nimg.1996.0066 · Cited by 2,025
Laruelle, M., Abi-Dargham, A., van Dyck, C. H., Gil, R., D'Souza, C. D., Erdos, J., McCance, E., Rosenblatt, W., Fingado, C., Zoghbi, S. S., et al. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.17.9235 · Cited by 1,291
Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action
Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F. I., Bäbler, A., Vogel, H., & Hell, D. (1998) · NeuroReport · doi:10.1097/00001756-199812010-00024 · Cited by 1,018
Self-citationPatterns of Cerebral Blood Flow in Schizophrenia
Liddle, P. F., Friston, K. J., Frith, C., Hirsch, S. R., Jones, T., & Frackowiak, R. S. J. (1992) · The British Journal of Psychiatry · doi:10.1192/bjp.160.2.179 · Cited by 899
Hypofrontality in Neuroleptic-Naive Patients and in Patients With Chronic Schizophrenia
Andreasen, N. C. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820120031006 · Cited by 883
Serotonin-dopamine interaction and its relevance to schizophrenia
Kapur, S., & Remington, G. (1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.4.466 · Cited by 826
The Early Symptoms of Schizophrenia
Chapman, J. (1966) · British Journal of Psychiatry · doi:10.1192/bjp.112.484.225 · Cited by 675
Vollenweider, F. (1997) · Neuropsychopharmacology · doi:10.1016/s0893-133x(96)00246-1 · Cited by 444
Self-citationThe Mechanism of Action of Novel Antipsychotic Drugs
Meltzer, H. Y. (1991) · Schizophrenia Bulletin · doi:10.1093/schbul/17.2.263 · Cited by 412
Serotonin Uptake Sites and Serotonin Receptors Are Altered in the Limbic System of Schizophrenics
Joyce, J. N., Shane, A. L., Lexow, N., Winokur, A., Casanova, M. F., & Kleinman, J. E. (1993) · Neuropsychopharmacology · doi:10.1038/npp.1993.32 · Cited by 340
SPECT imaging of striatal dopamine release after amphetamine challenge.
Laruelle, M. A., Abi‐Dargham, A., van Dyck, C. H., Rosenblatt, W., Zea‐Ponce, Y., Zoghbi, S. S., Baldwin, R. M., Charney, D. S., Hoffer, P. B., & Kung, H. F. (1995) · PubMed · Cited by 333
Frontostriatal Disorder of Cerebral Metabolism in Never-Medicated Schizophrenics
Buchsbaum, M. S. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820120023005 · Cited by 326
Dewey, S. L., Smith, G. S., Logan, J., Brodie, J. D., Fowler, J. S., & Wolf, A. P. (1993) · Synapse · doi:10.1002/syn.890130407 · Cited by 283
Parsons, L. H., & Justice, J. B. (1993) · Brain Research · doi:10.1016/0006-8993(93)90984-u · Cited by 252
Gudelsky, G. A., & Nash, J. F. (1996) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1996.66010243.x · Cited by 252
Selective Abnormalities of Prefrontal Serotonergic Receptors in Schizophrenia
Laruelle, M. A. (1993) · Archives of General Psychiatry · doi:10.1001/archpsyc.1993.01820220066007 · Cited by 235
Hasler, F., Bourquin, D., Brenneisen, R., Bär, T., & Vollenweider, F. X. (1997) · Pharmaceutica Acta Helvetiae · doi:10.1016/s0031-6865(97)00014-9 · Cited by 234
Self-citationSerotonin-facilitated dopamine release in vivo: pharmacological characterization.
Benloucif, S., Keegan, M., & Galloway, M. P. (1993) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)38133-4 · Cited by 230
Facilitation of dopamine release in vivo by serotonin agonists: studies with microdialysis
Benloucif, S., & Galloway, M. P. (1991) · European Journal of Pharmacology · doi:10.1016/0014-2999(91)90658-d · Cited by 229
Decreased serotonin S2 and increased dopamine D2 receptors in chronic schizophrenics
Mita, T., Hanada, S., Nishino, N., Kuno, T., Nakai, H., Yamadori, T., Mizoi, Y., & Tanaka, C. (1986) · Biological Psychiatry · doi:10.1016/0006-3223(86)90332-x · Cited by 222
Dewey, S. L., Smith, G., Logan, J., Alexoff, D. L., Ding, Y., King, P., Pappas, N. R., Brodie, J. D., & Ashby, C. R. (1995) · Journal of Neuroscience · doi:10.1523/jneurosci.15-01-00821.1995 · Cited by 215
Siegel, B. V., Buchsbaum, M. S., Bunney, W. E., Gottschalk, L. A., Haier, R. J., Lohr, J. B., Lottenberg, S., Najafi, A., Nuechterlein, K. H., & Potkin, S. G. (1993) · American Journal of Psychiatry · doi:10.1176/ajp.150.9.1325 · Cited by 201
Increased frontal and reduced parietal glucose metabolism in acute untreated schizophrenia
Cleghorn, J. M., Garnett, E. S., Nahmias, C., Firnau, G., Brown, G. M., Kaplan, R. D., Szechtman, H., & Szechtman, B. (1989) · Psychiatry Research · doi:10.1016/0165-1781(89)90040-1 · Cited by 197
Differential interactions of indolealkylamines with 5-hydroxytryptamine receptor subtypes
McKenna, D. J., Repke, D. B., Lo, L., & Peroutka, S. J. (1990) · Neuropharmacology · doi:10.1016/0028-3908(90)90001-8 · Cited by 195
Serotonin microinfusion into the ventral tegmental area increases accumbens dopamine release
Guan, X.-M., & McBride, W. J. (1989) · Brain Research Bulletin · doi:10.1016/0361-9230(89)90198-6 · Cited by 187
Multiple serotonin receptor subtypes modulate prepulse inhibition of the startle response in rats
Sipes, T. E., & Geyer, M. A. (1994) · Neuropharmacology · doi:10.1016/0028-3908(94)90074-4 · Cited by 184
"Psychedelic" Experiences in Acute Psychoses
Bowers, M. B. (1966) · Archives of General Psychiatry · doi:10.1001/archpsyc.1966.01730150016003 · Cited by 183
Reproducibility of repeated measures of carbon-11-raclopride binding in the human brain.
Volkow, N. D., Fowler, J. S., Wang, G., Dewey, S. L., Schlyer, D. J., MacGregor, R. R., Logan, J., Alexoff, D. L., Shea, C. E., & HITZEMANN, R. J. (1993) · PubMed · Cited by 178
Alterations in the cortical serotonergic system in schizophrenia: A postmortem study
Gurevich, E. V., & Joyce, J. N. (1997) · Biological Psychiatry · doi:10.1016/s0006-3223(97)00321-1 · Cited by 176
Catafau, A., Parellada, E., Lomeña, F. J., Bernardo, M., Pavı́a, J., Ros, D., SETOAIN, J., & González-Monclús, E. (1994) · PubMed · Cited by 173
Creese, I., Burt, D. R., & Snyder, S. H. (1975) · Life Sciences · doi:10.1016/0024-3205(75)90118-6 · Cited by 169
Sabri, O., Erkwoh, R., Schreckenberger, M., Owega, A., Saß, H., & Buell, U. (1997) · The Lancet · doi:10.1016/s0140-6736(96)08380-8 · Cited by 165
Ennis, C., Kemp, J. D., & Cox, B. (1981) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1981.tb00594.x · Cited by 163
Schmidt, C. J., Fadayel, G. M., Sullivan, C. K., & Taylor, V. L. (1992) · European Journal of Pharmacology · doi:10.1016/0014-2999(92)90819-p · Cited by 162
Activation of a 5-HT3 receptor releases dopamine from rat striatal slice
Blandina, P., Goldfarb, J., & Green, J. P. (1988) · European Journal of Pharmacology · doi:10.1016/0014-2999(88)90528-6 · Cited by 160
Serotonin2 (5-HT2) receptor binding in the frontal cortex of schizophrenic patients
Arora, R. C., & Meltzer, H. Y. (1991) · Journal of Neural Transmission · doi:10.1007/bf01244654 · Cited by 154
Hallucinogenic drug interactions with neurotransmitter receptor binding sites in human cortex
Pierce, P. A., & Peroutka, S. J. (1989) · Psychopharmacology · doi:10.1007/bf00443425 · Cited by 152
Serotonergic involvement in haloperidol-induced catalepsy.
Neal‐Beliveau, B. S., Joyce, J. N., & Lucki, I. (1993) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)38100-0 · Cited by 148
Bonhomme, N., Deurwaerdère, P. D., Moal, M. L., & Spampinato, U. (1995) · Neuropharmacology · doi:10.1016/0028-3908(94)00145-i · Cited by 143
Yamamoto, B. K., Nash, J. F., & Gudelsky, G. A. (1995) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)09555-2 · Cited by 142
Ebmeier, K. P., Blackwood, D. H. R., Murray, C. L., Souza, V., Walker, M., Dougall, N. J., Moffoot, A. P. R., O’Carroll, R. E., & Goodwin, G. M. (1993) · Biological Psychiatry · doi:10.1016/0006-3223(93)90002-u · Cited by 135
Schmidt, C. J., Sullivan, C. K., & Fedayal, G. M. (1994) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1994.62041382.x · Cited by 132
Early subjective experiences in schizophrenic episodes.
Freedman, B. J., & Chapman, L. J. (1973) · Journal of Abnormal Psychology · doi:10.1037/h0034952 · Cited by 130
Androgen modulates N-methyl-D-aspartate-mediated depolarization in CA1 hippocampal pyramidal cells
Pouliot, W. A., Handa, R. J., & Beck, S. G. (1996) · Synapse · doi:10.1002/(sici)1098-2396(199605)23:1 · Cited by 128
Palfreyman, M. G., Schmidt, C. J., Sorensen, S. M., Dudley, M. W., Kehne, J. H., Moser, P. C., Gittos, M. W., & Carr, A. A. (1993) · Psychopharmacology · doi:10.1007/bf02245008 · Cited by 125
Padich, R. A., McCloskey, T. C., & Kehne, J. H. (1996) · Psychopharmacology · doi:10.1007/bf02245610 · Cited by 119
Symptom Differences in Schizophrenia with Good and Poor Prognosis
McCabe, M., Fowler, R. C., Cadoret, R. J., & Winokur, G. (1972) · American Journal of Psychiatry · doi:10.1176/ajp.128.10.1239 · Cited by 117
Increased activation of indirect semantic associations under psilocybin
Spitzer, M., Thimm, M., Hermle, L., Holzmann-Erens, P., Kovar, K., Heimann, H., Gouzoulis‐Mayfrank, E., Kischka, U., & Schneider, F. W. (1996) · Biological Psychiatry · doi:10.1016/0006-3223(95)00418-1 · Cited by 115
The dopamine hypothesis of schizophrenia: limbic interactions with serotonin and norepinephrine
Joyce, J. N. (1993) · Psychopharmacology · doi:10.1007/bf02245004 · Cited by 113
Dreams, Hallucinogenic Drug States, and Schizophrenia: A Psychological and Biological Comparison
Fischman, L. G. (1983) · Schizophrenia Bulletin · doi:10.1093/schbul/9.1.73 · Cited by 107
Sipes, T. E., & Geyer, M. A. (1995) · Psychopharmacology · doi:10.1007/bf02245096 · Cited by 103
Marek, G. J., & Aghajanian, G. K. (1994) · European Journal of Pharmacology · doi:10.1016/0014-2999(94)90502-9 · Cited by 95
Parellada, E., Catafau, A. M., Bernardo, M., Lomeña, F., González-Monclús, E., & Setoain, J. (1994) · Psychiatry Research Neuroimaging · doi:10.1016/0925-4927(94)90021-3 · Cited by 88
Boulenguez, P., Rawlins, J. N. P., Chauveau, J., Joseph, M. H., Mitchell, S. N., & Gray, J. A. (1996) · Neuropharmacology · doi:10.1016/s0028-3908(96)00099-8 · Cited by 81
Buckholtz, N. S., Zhou, D.-F., Freedman, D. X., & Potter, W. Z. (1990) · PubMed · Cited by 80
de Belleroche, J., & Bradford, H. F. (1980) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1980.tb07879.x · Cited by 80
Serotonergic modulation of dopamine measured with [11C]raclopride and PET in normal human subjects
Smith, G. S., Dewey, S. L., Brodie, J. D., Logan, J., Vitkun, S. A., Simkowitz, P., Schloesser, R., Alexoff, D. L., Hurley, A., Cooper, T. B., et al. (1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.4.490 · Cited by 75
McKenna, D. J., Nazarali, A. J., Hoffman, A. J., Nichols, D. E., Mathis, C. A., & Saavedra, J. M. (1989) · Brain Research · doi:10.1016/0006-8993(89)91535-7 · Cited by 70
Nordström, A., Farde, L., Pauli, S., Litton, J., & Halldin, C. (1992) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.470070302 · Cited by 66
Westfall, T. C., & Tittermary, V. (1982) · Neuroscience Letters · doi:10.1016/0304-3940(82)90153-7 · Cited by 63
Deurwaerdère, P. D., L'hirondel, M., Bonhomme, N., Lucas, G., Chéramy, A., & Spampinato, U. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.68010195.x · Cited by 61
Ebmeier, K. P., Lawrie, S. M., Blackwood, D., Johnstone, E. C., & Goodwin, G. M. (1995) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.58.4.452 · Cited by 59
Tiihonen, J., Kuoppamäki, M., Syvälahti, E. K. G., Någren, K., Eronen, E., Hietala, J. A., & Bergman, J. R. (1996) · Psychopharmacology · doi:10.1007/bf02247377 · Cited by 53
History, Rationale and Potential of Human Experimental Hallucinogenic Drug Research in Psychiatry
Gouzoulis‐Mayfrank, E., Hermle, L., Thelen, B., & Sass, H. (1998) · Pharmacopsychiatry · doi:10.1055/s-2007-979348 · Cited by 50
Zazpe, A., Artaiz, I., & del Rı́o, J. A. (1994) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1994.tb17087.x · Cited by 39
Krebs-Thomson, K., & Geyer, M. A. (1996) · PubMed · Cited by 38
Madras, B. K., Meltzer, P. C., Liang, A. Y., Elmaleh, D. R., Babich, J. W., & Fischman, A. J. (1998) · Synapse · doi:10.1002/(sici)1098-2396(199806)29:2 · Cited by 37
Schmidt, C. J., Kehne, J. H., Carr, A., Fadayel, G. M., Humphreys, T. M., Kettler, H. J., McCloskey, T. C., Padich, R. A., Taylor, V. L., & Sorensen, S. M. (1993) · PubMed · Cited by 27
Nomikos, G. G., Arborelius, L., H��k, B. B., Hacksell, U., & Svensson, T. H. (1996) · Journal of Neural Transmission · doi:10.1007/bf01273152 · Cited by 26
de Belleroche, J., & Gardiner, I. M. (1982) · Journal of Neural Transmission · doi:10.1007/bf01276578 · Cited by 25
[Psychedelic experiences at the onset of productive episodes of endogenous psychoses].
Gouzoulis, E., Hermle, L., & Sass, H. (1994) · PubMed · Cited by 18
Molecular Neuroanatomy of 5-HT Receptors
Palacios, J. M., Waeber, C., Mengod, G., & Pompeiano, M. (1991) · Birkhäuser Basel eBooks · doi:10.1007/978-3-0348-7259-1_2 · Cited by 17
Models of Experience and Behavior in Psychotic Disorders
Heimann, H. L. (1986) · Pharmacopsychiatry · doi:10.1055/s-2007-1017170 · Cited by 4
Cited by
Sorted by citations
Nichols, D. E. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011478 · Cited by 1,762
“An effective dose of psilocybin, which lacks significant affinity for dopamine receptors, significantly decreased binding of the dopamine D2 antagonist [(11)C]raclopride in both the caudate nucleus and putamen, a finding that would be consistent with an increase inextracellulardopamine (Vollenweider et al., 1999).”
MethodResultHuman hallucinogen research: guidelines for safety
Johnson, M., Richards, W., & Griffiths, R. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108093587 · Cited by 1,203
Nichols, D. E. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2003.11.002 · Cited by 1,211
Imaging Synaptic Neurotransmission with in Vivo Binding Competition Techniques: A Critical Review
Laruelle, M. (2000) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-200003000-00001 · Cited by 944
Neuroanatomical and Neurochemical Substrates of Timing
Coull, J. T., Cheng, R., & Meck, W. H. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.113 · Cited by 852
“Psilocybin does not only directly bind to 5-HT2A receptors but also indirectly increases DA concentration in the dorsal striatum of the BG, as measured by decreased D2 receptor occupancy in an [11C] raclopride PET study (Vollenweider et al, 1999).”
Method
Metadata
- Authors
- Vollenweider, F.
- Affiliations
- University Hospital Zurich (CH)
- Corresponding author
- Vollenweider, F
- Venue
- Neuropsychopharmacology
- Published
- 1999-05
- Volume
- 20
- Issue
- 5
- Pages
- 424-433
- ISSN
- 0893-133X (ISSN-L)
- OpenAlex
- W1986425243
- Cited by
- 305
- References
- 73
- Citations by year
- 2026: 15 · 2025: 18 · 2024: 28 · 2023: 28 · 2022: 20 · 2021: 18 · 2020: 19 · 2019: 6 · 2018: 13 · 2017: 7 · 2016: 14 · 2015: 7 · 2014: 6 · 2013: 9 · 2012: 11
- FWCI
- 8.62
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Neuropsychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- DORA PSI (Paul Scherrer Institute) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- psilocybin, psychosis, serotonin, dopamine release, dopamine D2 receptor, [11C]raclopride, striatum, caudate nucleus, putamen, 5-HT2A receptor, 5-HT1A receptor, serotonin-dopamine interaction, hallucinations, depersonalization, schizophrenia
- MeSH terms
- Adult, Basal Ganglia, Dopamine, Hallucinogens, Humans, Male, Psilocybin, Psychometrics, Psychoses, Substance-Induced, Salicylamides, Serotonin, Tomography, Emission-Computed, Antipsychotic Agents, Dopamine Antagonists, Raclopride
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
